Bay 60-7550 (Synonyms: BAY 607550) |
Katalog-Nr.GC19512
One-Click Copy Product Info
|
Bay 60-7550 ist ein potenter und selektiver PDE2-Hemmer mit einem Ki von 3,8 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 439083-90-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Bay 60-7550 is a potent inhibitor of Phosphodiesterase 2 (PDE2) purified from bovine heart with an IC50 value of 2.0±0.7nM[1]. Bay 60-7550 increased cGMP and cAMP levels and promoted cGMP signaling[2]. Bay 60-7550 has been widely used in different animal models to improve depression-like behaviors and enhance brain function[3].
In vitro, Bay 60-7550 treatment (1µM) for 24h rescued HT-22 cells from the cytotoxicity induced by 50µM corticosterone and reversed down-regulation of CBP proteins induced by corticosterone[4]. Treatment with 1µM Bay 60-7550 for 48 hours blocked oxidative stress and apoptosis in mouse primary cortical neuronal cells treated with Aβ1-42 oligomers[5].
In vivo, Bay 60-7550 treatment via intraperitoneal injection at a dose of 3mg/kg twice daily for 4 days reduced ethanol preference and intake without affecting locomotor activity in C57BL/6J mice[6]. BAY 60-7550 treatment (p.o.) at a daily dose of 1mg/kg for 21 days alleviated bilateral common carotid artery occlusion (BCCAO)-induced behavioral deficits in mice and enhanced the expression of pCREB and BDNF proteins in the hippocampus of mice[7]. Intraperitoneal injection of BAY 60-7550 at a daily dose of 3mg/kg for 14 days reversed Aβ1-42-induced memory impairment in mice[8].
References:
[1] Boess F G, Hendrix M, van der Staay F J, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance[J]. Neuropharmacology, 2004, 47(7): 1081-1092.
[2] Masood A, Huang Y, Hajjhussein H, et al. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling[J]. The Journal of pharmacology and experimental therapeutics, 2009, 331(2): 690-699.
[3] Huang X, Xiaokaiti Y, Yang J, et al. Inhibition of phosphodiesterase 2 reverses gp91phox oxidase-mediated depression-and anxiety-like behavior[J]. Neuropharmacology, 2018, 143: 176-185.
[4] Xu Y, Pan J, Chen L, et al. Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway[J]. International Journal of Neuropsychopharmacology, 2013, 16(4): 835-847.
[5] Yan Y, Gao S, Avasthi S, et al. Protective effects of phosphodiesterase 2 inhibitor against Aβ1-42 induced neuronal toxicity[J]. Neuropharmacology, 2022, 213: 109128.
[6] Shi J, Liu H, Pan J, et al. Inhibition of phosphodiesterase 2 by Bay 60-7550 decreases ethanol intake and preference in mice[J]. Psychopharmacology, 2018, 235(8): 2377-2385.
[7] Soares L M, Meyer E, Milani H, et al. The phosphodiesterase type 2 inhibitor BAY 60-7550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity[J]. European Journal of Neuroscience, 2017, 45(4): 510-520.
[8] Ruan L, Du K, Tao M, et al. Phosphodiesterase-2 inhibitor bay 60-7550 ameliorates Aβ-induced cognitive and memory impairment via regulation of the HPA Axis[J]. Frontiers in cellular neuroscience, 2019, 13: 432.
| Cell experiment [1]: | |
Cell lines | HT-22 cells |
Preparation Method | HT-22 cells were cultured in DMEM medium containing 10% FBS at 37°C in 5% CO2. Cells were seeded in 96-well plates at a density of 1×105 cells/well. Cells were divided into three groups: control group, 50µM corticosterone treatment group, and 50µM corticosterone+1µM Bay 60-7550 experimental group. After 24 hours, 10µl MTT solution was added to each well and incubated for an additional 4 hours at 37°C. The medium in each well was then replaced with 200µl DMSO, and the absorbance at 570nm was measured. |
Reaction Conditions | 1µM; 24h |
Applications | Bay 60-7550 treatment significantly rescued HT-22 cells from corticosterone-induced cytotoxicity. |
| Animal experiment [2]: | |
Animal models | Male C57bL/6 mice |
Preparation Method | Male C57bL/6 mice (25-30g; 3 months of age) were housed at a controlled temperature (22±1°C) with a 12h/12h light/dark cycle (lights on at 7:00 am). The mice had ad libitum access to food and water. Transient cerebral ischemia was induced by BCCAO. Vehicle or BAY 60-7550 was administered by oral gavage (p.o.) at a dose of 1mg/kg/day for 21 days, followed by behavioral testing. |
Dosage form | 1mg/kg/day for 21 days; p.o. |
Applications | BAY 60-7550 treatment alleviated BCCAO-induced behavioral disorders and anxiety in mice. |
References: | |
| Cas No. | 439083-90-6 | SDF | |
| Überlieferungen | BAY 607550 | ||
| Canonical SMILES | O=C1N=C(NN2C1=C(N=C2[C@@H](CCCC3=CC=CC=C3)[C@@H](C)O)C)CC4=CC=C(C(OC)=C4)OC | ||
| Formula | C₂₇H₃₂N₄O₄ | M.Wt | 476.57 |
| Löslichkeit | Acetone: 10 mg/ml,DMSO: 10 mg/ml,Ethanol: 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0983 mL | 10.4916 mL | 20.9833 mL |
| 5 mM | 419.7 μL | 2.0983 mL | 4.1967 mL |
| 10 mM | 209.8 μL | 1.0492 mL | 2.0983 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)